1-15 of 15
Dennis J. Slamon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1365–1375.
https://doi.org/10.1158/1535-7163.MCT-23-0353
Published: 01 December 2023
View article titled, Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
Open the PDF for Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers in another window
Includes: Supplementary data
Journal Articles

Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies

Neil A. O'Brien, Holly K.T. Huang, Martina S.J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 751–761.
https://doi.org/10.1158/1535-7163.MCT-21-0847
Published: 04 May 2022
View article titled, Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Open the PDF for Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies in another window
Includes: Supplementary data
Journal Articles

Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo

Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Leverson, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (6): 1115–1126.
https://doi.org/10.1158/1535-7163.MCT-18-0743
Published: 03 June 2019
View article titled, Neutralization of BCL-2/X<sub>L</sub> Enhances the Cytotoxicity of T-DM1 <em>In Vivo</em>
Open the PDF for Neutralization of BCL-2/X<sub>L</sub> Enhances the Cytotoxicity of T-DM1 <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer

Marina Koutsioumpa, Hsiao-Wang Chen, Neil O'Brien, Filippos Koinis, Swapna Mahurkar-Joshi, Christina Vorvis, Artin Soroosh, Tong Luo, Shawnt Issakhanian, Allan J. Pantuck, Vassilis Georgoulias, Dimitrios Iliopoulos, Dennis J. Slamon, Alexandra Drakaki
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (7): 1430–1440.
https://doi.org/10.1158/1535-7163.MCT-17-1049
Published: 01 July 2018
View article titled, MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer
Open the PDF for MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

Neil O'Brien, Dylan Conklin, Richard Beckmann, Tong Luo, Kevin Chau, Josh Thomas, Ann Mc Nulty, Christophe Marchal, Ondrej Kalous, Erika von Euw, Sara Hurvitz, Colleen Mockbee, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 897–907.
https://doi.org/10.1158/1535-7163.MCT-17-0290
Published: 30 April 2018
View article titled, Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Open the PDF for Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

Michael F. Press, Catherine E. Ellis, Robert C. Gagnon, Tobias J. Grob, Marc Buyse, Ivonne Villalobos, Zhiyong Liang, Shafei Wu, Yung-Jue Bang, Shu-Kui Qin, Hyun Cheol Chung, Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Karen Afenjar, Yanling Ma, Monica C. Estrada, Douglas M. Robinson, Stefan J. Scherer, Guido Sauter, J. Randolph Hecht, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (1): 228–238.
https://doi.org/10.1158/1535-7163.MCT-15-0887
Published: 05 January 2017
View article titled, <em>HER2</em> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Open the PDF for <em>HER2</em> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib in another window
Includes: Supplementary data
Journal Articles

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 890–900.
https://doi.org/10.1158/1535-7163.MCT-12-0998
Published: 09 June 2013
View article titled, The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Open the PDF for The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth in another window
Includes: Supplementary data
Journal Articles

Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, Boris Winterhoff, Siân Jones, Victor E. Velculescu, Natarajan Venkatesan, Hong-Mei Rong, Sugandha Dandekar, Nitin Udar, Fritz Jänicke, Gerrit Los, Dennis J. Slamon, Gottfried E. Konecny
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 1002–1015.
https://doi.org/10.1158/1535-7163.MCT-12-0813
Published: 09 June 2013
View article titled, Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Open the PDF for Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells

Gottfried E. Konecny, Teodora Kolarova, Neil A. O'Brien, Boris Winterhoff, Guorong Yang, Jingwei Qi, Zhengdong Qi, Natarajan Venkatesan, Raul Ayala, Tong Luo, Richard S. Finn, Jessica Kristof, Chad Galderisi, Diana Graus Porta, Lee Anderson, Michael M. Shi, Alejandro Yovine, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5): 632–642.
https://doi.org/10.1158/1535-7163.MCT-12-0999
Published: 08 May 2013
View article titled, Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
Open the PDF for Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells in another window
Journal Articles

Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O'Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (4): 509–519.
https://doi.org/10.1158/1535-7163.MCT-12-0507
Published: 08 April 2013
View article titled, Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Open the PDF for Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (9): 1978–1987.
https://doi.org/10.1158/1535-7163.MCT-11-0730
Published: 06 September 2012
View article titled, Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Open the PDF for Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib in another window
Includes: Supplementary data
Journal Articles

Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis

Min Zhu, Romaine E. Saxton, Lillian Ramos, David D. Chang, Beth Y. Karlan, Judith C. Gasson, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (8): 1500–1508.
https://doi.org/10.1158/1535-7163.MCT-11-0046
Published: 08 August 2011
View article titled, Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis
Open the PDF for Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis in another window
Includes: Supplementary data
Journal Articles

Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines

Edward B. Garon, Richard S. Finn, Wylie Hosmer, Judy Dering, Charles Ginther, Shahriar Adhami, Naeimeh Kamranpour, Sharon Pitts, Amrita Desai, David Elashoff, Tim French, Paul Smith, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 1985–1994.
https://doi.org/10.1158/1535-7163.MCT-10-0037
Published: 07 July 2010
View article titled, Identification of Common Predictive Markers of <em>In vitro</em> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines
Open the PDF for Identification of Common Predictive Markers of <em>In vitro</em> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines in another window
Includes: Supplementary data
Journal Articles

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

Neil A. O'Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O'Donovan, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1489–1502.
https://doi.org/10.1158/1535-7163.MCT-09-1171
Published: 09 June 2010
View article titled, Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Open the PDF for Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib in another window
Includes: Supplementary data
Journal Articles

Abstract B232: Preclinical evaluation of AMG479 a fully human insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells

Gottfried E. Konecny, Kanthinh Manivong, Ellen Guorong, Ruth Glas, Judy Dering, Lee Anderson, Charles Ginther, Victor Velculescu, Frank Calzone, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B232.
https://doi.org/10.1158/1535-7163.TARG-09-B232
Published: 10 December 2009
View article titled, Abstract B232: Preclinical evaluation of AMG479 a fully human insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells